Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementation.

Journal of nephrology·2025
Same author

[The Outpatient Activity of the Onconephrology Clinic of Cremona in the First Semester of 2023].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2024
Same author

[Staphylococcus-associated glomerulonephritis without IgA deposits: a case report].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2022
Same author

Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism.

Nutrients·2022
Same author

Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2021
Same author

Combined renal proximal tubulopathy and crystal storing histiocytosis in a patient with κ light chain multiple myeloma.

Pathologica·2021

Related Experiment Video

Updated: May 11, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Hyperphosphataemia: treatment options.

Fabio Malberti1

  • 1Divisione di Nefrologia e Dialisi, Istituti Ospitalieri di Cremona, 26100, Cremona, Italy. f.malberti@ospedale.cremona.it

Drugs
|April 30, 2013
PubMed
Summary
This summary is machine-generated.

Hyperphosphataemia management in chronic kidney disease (CKD) involves diet and phosphate binders. While calcium-based binders are common, non-calcium options like sevelamer offer alternatives with potential cardiovascular benefits.

More Related Videos

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Related Experiment Videos

Last Updated: May 11, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Area of Science:

  • Nephrology
  • Clinical Pharmacology
  • Internal Medicine

Background:

  • Hyperphosphataemia is a common complication in chronic kidney disease (CKD), linked to increased cardiovascular risk.
  • It arises from impaired renal phosphate excretion or excessive phosphate load.
  • Effective management is crucial for improving outcomes in CKD patients.

Purpose of the Study:

  • To review the causes and management strategies for hyperphosphataemia in CKD.
  • To evaluate the efficacy and safety profiles of different phosphate binders.
  • To discuss the individualized approach to selecting phosphate binders.

Main Methods:

  • Literature review of studies on hyperphosphataemia in CKD.
  • Analysis of treatment options including dietary modifications and phosphate binders.
  • Comparison of calcium-based and non-calcium-based binders (sevelamer, lanthanum carbonate, magnesium salts).

Main Results:

  • Dietary restriction and phosphate binders are essential for controlling serum phosphorus levels in CKD.
  • Calcium-based binders are effective but associated with risks like hypercalcaemia and calcification.
  • Non-calcium binders offer alternatives, with sevelamer noted for potential cardiovascular benefits and no systemic accumulation.

Conclusions:

  • Phosphate binder selection should be individualized based on clinical factors, cost, and tolerability.
  • While non-calcium binders show promise, comparative data on hard outcomes like mortality are limited.
  • Balancing efficacy, safety, and cost is key in managing hyperphosphataemia in CKD.